List of Studies ( Metabolite:Linoleamide)
Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
---|---|---|---|---|---|---|---|
ST001680 | AN002740 | Metabolome of NAFLD in high fat diet mouse model | Liver | Mouse | Fatty liver disease | Weill Cornell Medicine | Abundance |
ST002758 | AN004475 | Metabolic responses of normal rat kidneys to a high salt intake (Plasma) | Blood | Rat | Medical College of Wisconsin | Area | |
ST002758 | AN004477 | Metabolic responses of normal rat kidneys to a high salt intake (Plasma) | Blood | Rat | Medical College of Wisconsin | Area | |
ST002760 | AN004485 | Metabolic responses of normal rat kidneys to a high salt intake (Kidney outer medulla) | Kidney outer medulla | Rat | Medical College of Wisconsin | Area | |
ST001143 | AN001883 | Microbial depletion and ozone exposure - Lung tissue (part I) | Lung | Mouse | Asthma | Harvard School of Public Health | Area under curve |
ST002051 | AN003338 | The apicomplexan parasite Toxoplasma gondii forms bradyzoite-containing tissue cysts that cause chronic and drug-tolerant infections. | Cultured cells | Toxoplasma gondii | Parasitic infection | Robert Koch-Institute | counts |
ST003362 | AN005504 | Metabolomics analysis of Glioblastoma (GBM) cell line U251 labeled by 13C-glutamine after treatment with pimozide | Cultured cells | Human | Cancer | The Ohio State University | Counts |
ST003362 | AN005506 | Metabolomics analysis of Glioblastoma (GBM) cell line U251 labeled by 13C-glutamine after treatment with pimozide | Cultured cells | Human | Cancer | The Ohio State University | Counts |
ST001403 | AN002345 | Ontogeny related changes in the pediatric liver metabolome (part-II) | Liver | Human | Moffitt Cancer Center | estimated abundances | |
ST001795 | AN002915 | Changes in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib (part I) | Mesenteric lymph | Mouse | Obesity | Monash Institute of Pharmaceutical Sciences | height |
ST001796 | AN002917 | Changes in mesenteric lymph lipid profile of mice upon high-fat diet with and without Celecoxib | Mesenteric lymph | Mus musculus | Diabetes | Monash Institute of Pharmaceutical Sciences | height |
ST001788 | AN002899 | β-Adrenergic regulation of metabolism in macrophages (part-IV) | Macrophages | Human | Monash University | Intensity | |
ST003044 | AN004994 | A High-Fat Eucaloric Diet Induces Reprometabolic Syndrome of Obesity in Normal Weight Women - lipidomics | Blood | Human | Obesity | University of Colorado Denver | peak area |
ST000311 | AN000495 | TC and B6 untreated plasma in lupus-prone mice | Blood | Mouse | Lupus | University of Florida | Peak area |
ST002461 | AN004015 | Untargeted metabolomics of HUVECs subjected to hypoxia-reoxygenation | Cultured cells | Human | Hypoxia | Tulane University School of Medicine | Peak area |
ST003348 | AN005483 | An integrated LC-MS analysis of the biometric characteristics of different time cohorts of race walkers - untargeted | Blood | Human | The First Affiliated Hospital of Dalian Medical University | Peak area | |
ST003053 | AN005006 | Providing insight into the mechanism of action of Cationic Lipidated Oligomers (CLOs) using metabolomics | Bacterial cells | Staphylococcus aureus | Bacterial infection | Monash University | peak height |
ST000311 | AN000497 | TC and B6 untreated plasma in lupus-prone mice | Blood | Mouse | Lupus | University of Florida | Peak height |
ST000403 | AN000642 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes | Cells | Human | Monash Institute of Pharmaceutical Sciences, Monash University | Peak height | |
ST000539 | AN000818 | Metabolomics-based elucidation of active metabolic pathways in erythrocytes and HSC-derived reticulocytes (part II) | Cells | Human | Monash Institute of Pharmaceutical Sciences, Monash University | Peak height | |
ST001275 | AN002116 | Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-II) | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | Peak height |
ST000421 | AN000663 | ms3076 T1D poor glycemic control and control samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
ST000421 | AN000665 | ms3076 T1D poor glycemic control and control samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
ST000422 | AN000669 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
ST001205 | AN002006 | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites | Cultured cells | Human | Malaria | Monash University | Peak intensity |
ST001205 | AN002006 | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites | Cultured cells | Plasmodium falciparum | Malaria | Monash University | Peak intensity |
ST001547 | AN002576 | β-Adrenergic regulation of metabolism in macrophages | Macrophages | Human | Monash University | Peak intensity | |
ST001548 | AN002578 | β-Adrenergic regulation of metabolism in macrophages (part-II) | Macrophages | Human | Monash University | Peak intensity | |
ST001549 | AN002580 | β-Adrenergic regulation of metabolism in macrophages (part-III) | Macrophages | Human | Monash University | Peak intensity | |
ST000451 | AN000707 | The alpha-1A adrenergic receptor agonist A61603 reduces cardiac polyunsaturated fatty acid-Heart raw data | Muscle | Mouse | University of North Carolina | Peak values (scaled) | |
ST000452 | AN000708 | The alpha-1A adrenergic receptor agonist A61603 reduces cardiac polyunsaturated fatty acid-Serum raw data | Blood | Mouse | University of North Carolina | Peak values (scaled) | |
ST000899 | AN001463 | Alterations in Lipid, Amino Acid, and Energy Metabolism Distinguish Crohn Disease from Ulcerative Colitis and Control Subjects by Serum Metabolomic Profiling | Blood | Human | Inflammatory bowel disease | Vanderbilt University Medical Center | raw area counts |
ST002094 | AN003420 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |
ST002094 | AN003421 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |
ST000047 | AN000081 | Identification of altered metabolic pathways in Alzheimer's disease, mild cognitive impairment and cognitively normals using Metabolomics (CSF) | Cerebrospinal fluid | Human | Alzheimers disease | Mayo Clinic | Raw MS Intensities |
ST001404 | AN002346 | Ontogeny related changes in the pediatric liver metabolome (part-III) | Liver | Human | Moffitt Cancer Center | Relative Abundance | |
ST002017 | AN003287 | Multi-omic analysis of the microbiome and metabolome in healthy subjects (blood) | Blood | Human | Vanderbilt University Medical Center | scaled imputed | |
ST002018 | AN003288 | Multi-omic analysis of the microbiome and metabolome in healthy subjects (feces) | Feces | Human | Vanderbilt University Medical Center | scaled imputed | |
ST000974 | AN001595 | GC6-74 matabolomic of TB (Part 1: Plasma) | Blood | Human | Tuberculosis | Max Planck Institute for Infection Biology | scaled units |
ST001175 | AN001950 | Multi-omics analysis demonstrates unique mode of action of a potent new antimalarial compound, JPC-3210, against Plasmodium falciparum | Plasmodium cells | Plasmodium falciparum | Malaria | Monash University | Signal Intensity |